IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).

The healthcare sector is divided. We analyze 10 high-conviction small-cap opportunities with 30-50% upside, featuring Viking Therapeutics and Hims & Hers.

FitLife Brands (NASDAQ: FTLF) is a small-cap wellness roll-up at a pivotal moment. With the recent acquisition of Irwin Naturals, the company has a clear path to double revenues and significantly expand margins by applying its e-commerce playbook to Irwin's retail-heavy portfolio.

Geopolitics is fueling a massive order book for M-Tron (MPTI). With a $58.8M backlog, this small-cap defense player is a critical supplier for modern warfare. But can margins recover from tariff headwinds?

Great tech, poor visibility. While Aehr's (AEHR) burn-in systems are essential for the AI supply chain, management's refusal to provide guidance makes the near-term risk too high. Here is why we are waiting.